• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Polio - Pipeline Review, H2 2012 Product Image

Polio - Pipeline Review, H2 2012

  • ID: 2245054
  • September 2012
  • 49 pages
  • Global Markets Direct

Polio – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Polio - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Polio, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Polio. Polio - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Polio.
- A review of the Polio products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- READ MORE >

2
List of Tables 4
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Polio Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Polio 8
Polio Therapeutics under Development by Companies 10
Polio Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Polio Therapeutics – Products under Development by Companies 14
Polio Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Polio Therapeutics Development 16
Sanofi-Aventis 16
GlaxoSmithKline plc 17
Merck & Co., Inc. 18
Takeda Pharmaceutical Company Limited 19
Panacea Biotec Limited 20
Polio – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
GSK-2036874A - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
GSK2202083A + Prevenar 13 + Rotarix - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Inactivated poliomyelitis vaccine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
GSK-217744 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
DTP-HepB-Polio-Hib - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Quadracel - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
V419 + Prevnar 13 + RotaTeq - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 35
Hexaxim - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SP-059 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
KD-332 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Easysix - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
TAK-361S - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Polio Therapeutics – Drug Profile Updates 41
Polio Therapeutics – Discontinued Products 44
Polio Therapeutics - Dormant Products 45
Polio – Product Development Milestones 46
Featured News & Press Releases 46
Nov 16, 2011: Quadrivalent Vaccine TAK-361S Enters Into Phase II Clinical Trials In Japan 46
Oct 26, 2000: Hexavalent pediatric vaccines licensed in EU 46
Apr 23, 1993: FDA Approval of Use of a New Haemophilus b Conjugate Vaccine and a Combined Diphtheria-Tetanus-Pertussis and Haemophilus b Conjugate Vaccine for Infants and Children 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49

List of Tables
Number of Products Under Development for Polio, H2 2012 8
Products under Development for Polio – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Sanofi-Aventis, H2 2012 16
GlaxoSmithKline plc, H2 2012 17
Merck & Co., Inc., H2 2012 18
Takeda Pharmaceutical Company Limited, H2 2012 19
Panacea Biotec Limited, H2 2012 20
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Polio Therapeutics – Drug Profile Updates 41
Polio Therapeutics – Discontinued Products 44
Polio Therapeutics – Dormant Products 45

List of Figures
Number of Products under Development for Polio, H2 2012 8
Products under Development for Polio – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos